Cargando…

Toward Targeted Therapies in Oesophageal Cancers: An Overview

SIMPLE SUMMARY: Prognosis for patients with oesophageal cancer is poor, because of its aggressive nature and the lack of targeted therapies. Advances in cancer biology and sequencing technology have enabled the selection of targeted therapies for individual patients with various types of tumors, suc...

Descripción completa

Detalles Bibliográficos
Autores principales: Bregni, Giacomo, Beck, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946490/
https://www.ncbi.nlm.nih.gov/pubmed/35326673
http://dx.doi.org/10.3390/cancers14061522
_version_ 1784674205732700160
author Bregni, Giacomo
Beck, Benjamin
author_facet Bregni, Giacomo
Beck, Benjamin
author_sort Bregni, Giacomo
collection PubMed
description SIMPLE SUMMARY: Prognosis for patients with oesophageal cancer is poor, because of its aggressive nature and the lack of targeted therapies. Advances in cancer biology and sequencing technology have enabled the selection of targeted therapies for individual patients with various types of tumors, such as breast or lung cancers as well as melanoma. However, precision oncology for patients with oesophageal cancer is still virtually non-existent. This review outlines the recent advances in oesophageal molecular profiling and the outcome of clinical trials based on targeted therapies in this disease. The signaling pathways that should be further investigated and the impact of tumor heterogeneity on resistance to therapy are also discussed. ABSTRACT: Oesophageal cancer is one of the leading causes of cancer-related death worldwide. Oesophageal cancer occurs as squamous cell carcinoma (ESCC) or adenocarcinoma (EAC). Prognosis for patients with either ESCC or EAC is poor, with less than 20% of patients surviving more than 5 years after diagnosis. A major progress has been made in the development of biomarker-driven targeted therapies against breast and lung cancers, as well as melanoma. However, precision oncology for patients with oesophageal cancer is still virtually non-existent. In this review, we outline the recent advances in oesophageal cancer profiling and clinical trials based on targeted therapies in this disease.
format Online
Article
Text
id pubmed-8946490
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89464902022-03-25 Toward Targeted Therapies in Oesophageal Cancers: An Overview Bregni, Giacomo Beck, Benjamin Cancers (Basel) Review SIMPLE SUMMARY: Prognosis for patients with oesophageal cancer is poor, because of its aggressive nature and the lack of targeted therapies. Advances in cancer biology and sequencing technology have enabled the selection of targeted therapies for individual patients with various types of tumors, such as breast or lung cancers as well as melanoma. However, precision oncology for patients with oesophageal cancer is still virtually non-existent. This review outlines the recent advances in oesophageal molecular profiling and the outcome of clinical trials based on targeted therapies in this disease. The signaling pathways that should be further investigated and the impact of tumor heterogeneity on resistance to therapy are also discussed. ABSTRACT: Oesophageal cancer is one of the leading causes of cancer-related death worldwide. Oesophageal cancer occurs as squamous cell carcinoma (ESCC) or adenocarcinoma (EAC). Prognosis for patients with either ESCC or EAC is poor, with less than 20% of patients surviving more than 5 years after diagnosis. A major progress has been made in the development of biomarker-driven targeted therapies against breast and lung cancers, as well as melanoma. However, precision oncology for patients with oesophageal cancer is still virtually non-existent. In this review, we outline the recent advances in oesophageal cancer profiling and clinical trials based on targeted therapies in this disease. MDPI 2022-03-16 /pmc/articles/PMC8946490/ /pubmed/35326673 http://dx.doi.org/10.3390/cancers14061522 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Bregni, Giacomo
Beck, Benjamin
Toward Targeted Therapies in Oesophageal Cancers: An Overview
title Toward Targeted Therapies in Oesophageal Cancers: An Overview
title_full Toward Targeted Therapies in Oesophageal Cancers: An Overview
title_fullStr Toward Targeted Therapies in Oesophageal Cancers: An Overview
title_full_unstemmed Toward Targeted Therapies in Oesophageal Cancers: An Overview
title_short Toward Targeted Therapies in Oesophageal Cancers: An Overview
title_sort toward targeted therapies in oesophageal cancers: an overview
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946490/
https://www.ncbi.nlm.nih.gov/pubmed/35326673
http://dx.doi.org/10.3390/cancers14061522
work_keys_str_mv AT bregnigiacomo towardtargetedtherapiesinoesophagealcancersanoverview
AT beckbenjamin towardtargetedtherapiesinoesophagealcancersanoverview